ANNEX. (a) the title of the second column is replaced by the following: 'Chemical name';

Transcription

1 EN ANNEX Annex VI to Regulation (EC) No 1272/2008 i amended a follow: (1) in Part 1, the heading of point i replaced by the following: 'Chemical name'; (2) in Part 3, Table 3.1 i amended a follow: (a) the title of the econd column i replaced by the following: 'Chemical name'; (b) the title of the penultimate column i replaced by the following: 'Specific *' '* for oral and dermal expoure route are expreed in mg/kg bw, which tand for milligram per kilogram bodyweight.' (c) the entry correponding to index number i deleted; (d) the entrie correponding to index number , , , , , , , , , , , , , X, , , and are replaced by the following entrie repectively: Index No Chemical name EC No CAS No Claification Labelling Specific Cla 1

2 ioproturon (ISO); 3-(4-iopropylphenyl)-1,1-dimethylurea Cla Carc. 2 STOT RE 2 (blood) (blood) M=10 M= phomet (ISO); S-[(1,3-dioxo-1,3-dihydro-2H-ioindol-2- yl)methyl] O,O-dimethyl phophorodithioate; O,O-dimethyl-S-phthalimidomethyl phophorodithioate Repr. 2 STOT SE 1 H370 H370 M= thifenulfuron-methyl (ISO); methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2- ylcarbamoylulfamoyl)thiophene-2-carboxylate M= odium hypochlorite, olution... % Cl active Skin Corr. 1B EUH031 M=10 M=1 B potaium permanganate Ox. Sol. 2 Repr. 2 * H272 GHS03 H272 ' colecalciferol; cholecalciferol; vitamin D STOT RE 1 H300 H372 H300 H372 inhalation: ATE = 0,05 mg/l (dut or mit) dermal: ATE = 50 mg/kg bw? oral: ATE = 35 mg/kg bw STOT RE 1; 2

3 Cla H372: C 3 % STOT RE 2; : 0,3 % C < 3 % chlorocreol; 4-chloro-m-creol; 4-chloro-3-methylphenol Skin Corr. 1C STOT SE 3 Skin Sen. 1B Aquatic Chronic 3 H ,2-dihydroxybenzene; pyrocatechol Carc. 1Β Muta. 2 Skin Irrit. 2 Eye Irrit. 2 H341 H311 H341 H311 oral: ATE = 300 mg/kg bw dermal: ATE = 600 mg/kg bw tert-butylphenol Repr. 2 Skin Irrit acetaldehyde; ethanal Flam. Liq. 1 Carc. 1B Muta. 2 STOT SE 3 Eye Irrit. 2 H224 H341 GHS02 H224 H benzyl-2-dimethylamino-4'- morpholinobutyrophenone Repr. 1B 3

4 Cla maleic anhydride STOT RE 1 Skin Corr. 1B Rep. Sen. 1 Skin Sen. 1A uccinic anhydride Skin Corr. 1 Rep. Sen. 1 Skin Sen. 1 H372 (repiratory H334 H334 H372 (repiratory H334 H334 EUH071 EUH071 Skin Sen. 1A; : C 0,001% X iobutyl methacrylate Flam. Liq. 3 STOT SE 3 Skin Irrit. 2 Skin Sen. 1B H226 GHS02 H226 D quizalofop-p-tefuryl (ISO); (+/-) tetrahydrofurfuryl (R)-2-[4-(6- chloroquinoxalin-2- yloxy)phenyloxy]propionate Carc. 2 Repr. 2 STOT RE 2 d d M= reaction ma of 5-chloro-2-methyl-2Hiothiazol-3-one and 2-methyl-2H-iothiazol-3- one (3:1) Skin Corr. 1C Skin Sen. 1A EUH071 Skin Corr. 1C; : C 0,6% Skin Irrit. 2; : 0,06% C < 0,6% ; : C 0,6% Eye Irrit. 2; : 0,06% C < 0,6% Skin Sen. 1A; : C 0,0015% B 4

5 Cla M=100 M= propiconazole (ISO); (2RS,4RS;2RS,4SR)-1- {[2-(2,4-dichlorophenyl)-4-propyl-1,3- dioxolan-2-yl]methyl}-1h-1,2,4-triazole Repr. 1B Skin Sen. 1 M= nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine Aquatic Chronic 2 H300 H411 H300 H411 inhalation: ATE = 0.19 mg/l (dut or mit) dermal: ATE = 70 mg/kg bw oral: ATE= 5 mg/kg bw 5

6 (e) the following entrie are inerted in the appropriate place, following the order of the entrie et out in Table 3.1: Index No Chemical name EC No CAS No Claification Labelling Specific X ioeugenol; [1] (E)-2-methoxy-4-(prop-1-enyl)phenol; [2] (Z)-2-methoxy-4-(prop-1-enyl)phenol [3] [1] [2] [3] [1] [2] [3] Cla Skin Sen. 1A Conc. Limit, Skin Sen. 1A; : C 0,01% ,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1- yl]cyclopropanecarboxylate; epilonmetofluthrin iopropyl (2E,4E,7S)-11-methoxy-3,7,11- trimethyldodeca-2,4-dienoate; S-methoprene STOT SE 1 STOT RE H370 H370 M=100 M= pinoxaden (ISO); 8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5- tetrahydro-7h-pyrazolo[1,2- d][1,4,5]oxadiazepin-9-yl 2,2- dimethylpropanoate Repr. 2 Eye Irrit. 2 STOT SE 3 Skin Sen. 1A Aquatic Chronic 3 H412 inhalation: ATE = 4,63 mg/l (dut or mit) oral: ATE = 500 mg/kg 6

7 tetramethrin (ISO); (1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-ioindol- 2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1- en-1-yl)cyclopropanecarboxylate (1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-ioindol- 2-yl)methyl (1R-tran)-2,2-dimethyl-3-(2- methylprop-1-enyl)cyclopropanecarboxylate meoulfuron-methyl (ISO); methyl 2-[(4,6-dimethoxypyrimidin-2- ylcarbamoyl)ulfamoyl]-α- (methaneulfonamido)-p-toluate; Cla Carc. 2 STOT SE Carc. 2 STOT SE H371 H371 Conc. Limit, H371 M=100 H371 M=100 M=100 M=100' pirodiclofen (ISO); 3-(2,4-dichlorophenyl)-2-oxo-1- oxapiro[4.5]dec-3-en-4-yl 2,2- dimethylbutyrate Carc. 1B Repr. 2 STOT RE 2 Skin Sen. 1B M= X odium methyl [(4- aminophenyl)ulphonyl]carbamate; odium methyl (EZ)-ulfanilylcarbonimidate; aulamodium Skin Sen. 1 M= alicylic acid Repr. 2 ' 7

8 flutianil (ISO); (2Z)-{[2-fluoro-5- (trifluoromethyl)phenyl]thio}[3-(2- methoxyphenyl)-1,3-thiazolidin-2- ylidene]acetonitrile reaction ma of 1-[2-(2- aminobutoxy)ethoxy]but-2-ylamine and 1- ({[2-(2- aminobutoxy)ethoxy]methyl}propoxy)but-2- ylamine Cla Repr. 2 Skin Corr. 1B 2-methyliothiazol-3(2H)-one Skin Corr. 1B Skin Sen. 1A pyroxulam (ISO); N-(5,7-dimethoxy[1,2,4]triazolo[1,5- a]pyrimidin-2-yl)-2-methoxy-4- (trifluoromethyl)pyridine-3-ulfonamide Skin Sen. 1 H311 Conc. Limit, H311 EUH071' EUH071 Skin Sen. 1A; : C 0,0015% M=10 M= X 1-vinylimidazole Repr. 1B Repr. 1B; : C 0,03% amiulbrom (ISO); 3-(3-bromo-6-fluoro-2-methylindol-1- ylulfonyl)-n,n-dimethyl-1h-1,2,4-triazole-1- ulfonamide Carc. 2 Eye Irrit. 2 M=10 M=10 8